Lux receives US FDA complete response letter for uveitis drug
This article was originally published in Scrip
Executive Summary
Lux Biosciences has received a complete response letter from the US FDA for Luveniq (oral voclosporin, LX211; licensed from Isotechnika Pharma), its treatment candidate for non-infectious uveitis. It requested that an additional clinical trial is conducted in order for an approval to be considered. Lux said it would conduct an additional pivotal study of Luveniq, which it expects to begin before the end of the year.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.